3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Melanoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
29
Gemcitabine
16
Cyclophosphamide
14
Nivolumab
12
Carboplatin
12
Capecitabine
11
Trastuzumab
9
Paclitaxel
9
Magnetic Resonance Spectroscopy
8
Irinotecan
8
Bevacizumab
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
olaparib
7
fludarabine
7
Docetaxel
7
spartalizumab
6
aldesleukin
6
Drug Therapy
6
Cisplatin
6
durvalumab
5
atezolizumab
5
Standard of Care
5
Specimen Handling
5
Oxaliplatin
5
Biopsy
5
sargramostim
4
palbociclib
4
niraparib
4
enzalutamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
LY3300054
×
Breast
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled